Snapshot from Jul 19, 2026 at 14:14 UTC. For live data and tracking: View Live
Events / Business / Eli Lilly launches Tanstrive in India
Business drug launch

Eli Lilly launches Tanstrive in India

Analysis based on 8 articles · First reported Jun 25, 2026 · Last updated Jun 25, 2026

Sentiment
60
Attention
4
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The launch of Tanstrive by Eli Lilly and Company in India is expected to positively impact the pharmaceutical market by introducing a new targeted cancer therapy. This could lead to increased revenue for Eli Lilly and Company and improved treatment outcomes for patients in India, potentially influencing healthcare investment in precision oncology.

Pharmaceuticals Healthcare
Event Summary

Eli Lilly and Company India has launched its cancer treatment drug, Tanstrive (selpercatinib), in India. This follows marketing authorization from the India — Central Drugs Standard Control Organisation for patients with locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene. Tanstrive is an oral therapy designed to selectively target RET alterations, blocking abnormal signaling pathways that drive tumor growth. It is available in various tablet strengths and is priced at Rs 2.15 lakh per box for a 14-day treatment regimen. Winslow Tucker, President and General Manager of Eli Lilly and Company (India), stated that Tanstrive represents a significant step forward in precision oncology, expanding access to targeted therapies for patients in India. Dr Rahul Kapur, Senior Director, Medical, Eli Lilly and Company (India), highlighted its importance as the first and only selective RET inhibitor approved in India for RET-altered solid tumors, emphasizing biomarker-guided treatment.

Entities Involved
stock
Eli Lilly and Company
Eli Lilly and Company has launched its cancer drug Tanstrive in India, expanding its market presence and offering a new treatment option for patients with RET-altered cancers. This launch is expected to positively impact the company's revenue and reputation in the Indian market.
Importance 100.0 Sentiment 70.0
cnt
India
India's healthcare sector benefits from the availability of a new targeted cancer therapy, Tanstrive, which addresses a specific genetic alteration in various solid tumors. This improves treatment options for Indian patients.
Importance 80.0 Sentiment 50.0
govactor
India — Central Drugs Standard Control Organisation
The India — Central Drugs Standard Control Organisation provided marketing authorization for Tanstrive, enabling its launch in India and ensuring regulatory compliance for the new drug.
Importance 70.0 Sentiment 50.0
per
Winslow Tucker
Winslow Tucker, President and General Manager of Eli Lilly and Company (India), highlighted the significance of Tanstrive in advancing precision oncology and expanding access to targeted therapies in India.
Importance 50.0 Sentiment 60.0
per
Rahul Kapur
Dr Rahul Kapur, Senior Director, Medical, Eli Lilly and Company (India), emphasized Tanstrive's role as the first and only selective RET inhibitor approved in India for RET-altered solid tumors, underscoring the importance of biomarker-guided treatment.
Importance 40.0 Sentiment 60.0
Relationships
India related ↔ India — Central Drugs Standard Control Organisation
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.